Pfizer Debt to Equity Ratio 2010-2022 | PFE

Current and historical debt to equity ratio values for Pfizer (PFE) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Pfizer debt/equity for the three months ending June 30, 2022 was 0.39.
Pfizer Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2022-06-30 $107.82B $87.47B 1.23
2022-03-31 $101.16B $82.69B 1.22
2021-12-31 $104.01B $77.46B 1.34
2021-09-30 $103.22B $75.97B 1.36
2021-06-30 $99.61B $70.32B 1.42
2021-03-31 $89.95B $68.87B 1.31
2020-12-31 $90.76B $63.47B 1.43
2020-09-30 $113.49B $65.50B 1.73
2020-06-30 $113.37B $64.56B 1.76
2020-03-31 $101.00B $65.34B 1.55
2019-12-31 $104.15B $63.45B 1.64
2019-09-30 $105.05B $65.40B 1.61
2019-06-30 $96.27B $59.92B 1.61
2019-03-31 $96.26B $59.16B 1.63
2018-12-31 $95.66B $63.76B 1.50
2018-09-30 $96.17B $71.66B 1.34
2018-06-30 $94.86B $70.12B 1.35
2018-03-31 $94.07B $70.54B 1.33
2017-12-31 $100.14B $71.66B 1.40
2017-09-30 $111.04B $61.11B 1.82
2017-06-30 $109.86B $58.69B 1.87
2017-03-31 $110.04B $58.75B 1.87
2016-12-31 $111.78B $59.84B 1.87
2016-09-30 $114.83B $63.60B 1.81
2016-06-30 $107.59B $63.07B 1.71
2016-03-31 $99.58B $63.35B 1.57
2015-12-31 $102.38B $65.00B 1.58
2015-09-30 $103.74B $67.12B 1.55
2015-06-30 $93.70B $67.18B 1.40
2015-03-31 $93.05B $67.59B 1.38
2014-12-31 $95.94B $71.62B 1.34
2014-09-30 $93.06B $78.31B 1.19
2014-06-30 $95.66B $76.96B 1.24
2014-03-31 $93.74B $78.07B 1.20
2013-12-31 $95.48B $76.62B 1.25
2013-09-30 $97.17B $78.35B 1.24
2013-06-30 $100.36B $78.98B 1.27
2013-03-31 $104.57B $82.83B 1.26
2012-12-31 $104.12B $81.68B 1.28
2012-09-30 $100.49B $82.12B 1.22
2012-06-30 $102.88B $79.96B 1.29
2012-03-31 $102.01B $83.68B 1.22
2011-12-31 $105.38B $82.62B 1.28
2011-09-30 $105.60B $90.53B 1.17
2011-06-30 $106.94B $88.96B 1.20
2011-03-31 $104.42B $90.53B 1.15
2010-12-31 $106.75B $88.27B 1.21
2010-09-30 $103.35B $88.07B 1.17
2010-06-30 $104.19B $86.88B 1.20
2010-03-31 $105.03B $90.08B 1.17
2009-12-31 $122.50B $90.45B 1.35
2009-09-30 $75.04B $66.25B 1.13
2009-06-30 $76.10B $63.24B 1.20
2009-03-31 $62.49B $60.44B 1.03
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $245.989B $81.288B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $435.655B 16.59
Eli Lilly (LLY) United States $292.179B 37.05
AbbVie (ABBV) United States $249.673B 10.61
Merck (MRK) United States $218.318B 11.40
Novo Nordisk (NVO) Denmark $215.616B 28.44
Novartis AG (NVS) Switzerland $165.082B 12.17